This site is intended for healthcare professionals

Round Up Email May 2025

In this month's Round Up highlights include an update of the herpes zoster vaccine section, evidence relating to the use of semaglutide in MASH, and a section relating to the use of azathioprine in pregnancy.

  • Question 1

    Lyme disease – Is Lyme disease more common in the Summer or the Winter? The infection is spread through the bite of an infected tick of the genus Ixodes but for approximately how long does the tick need to be attached to transmit the Lyme disease bacterium? Antibiotic treatment is highly effective, but approximately what proportion of patients have persistent symptoms despite antibiotic treatment?: Lyme disease

    With respect to Lyme disease, which statement is false?

  • Question 2

    Scabies section on GPnotebook – this section has been updated.: Scabies

    With respect to scabies, which statement is false

  • Question 3

    Herpes Zoster vaccination – this section summarises new evidence of protective effects of HZ vaccination with respect to dementia and cardiovascular disease.: Herpes zoster (shingles) vaccine

    With respect to the herpes zoster vaccination, which statement is false?

  • Question 4

    Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids – this section describes this recently NICE approved therapy option for the management of uterine fibroids.: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis

    With respect to relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids, which statement is false?

  • Question 5

    Azathioprine in pregnancy – this section of Gpnotebook has been updated.: Azathioprine during pregnancy

    With respect to the use of azathioprine during pregnancy, which statement is false?

  • Question 6

    Semaglutide in metabolic dysfunction–associated steatohepatitis (MASH) – this trial evidence has been summarised on Gpnotebook.: Semaglutide in metabolic dysfunction–associated steatohepatitis (MASH)

    With respect to the use of semaglutide in metabolic dysfunction–associated steatohepatitis (MASH), which statement is false?

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.